(Q43041709)

12 November 2017

1 reference

title

Prediction of response to interferon treatment of chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

Davis GL

1

1 reference

12 November 2017

publication date

1 July 1994

1 reference

12 November 2017

published in

Journal of Hepatology

1 reference

12 November 2017

volume

21

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

1-3

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Factors predictive of the response to interferon in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Results of long term interferon treatment in non A non B/C chronic active hepatitis. The French Group for the study of NANB/C chronic hepatitis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Factors useful in predicting the response to interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980128-2

7 January 2021

10.1016/S0168-8278(94)80128-2

Identifiers

DOI

1 reference

12 November 2017

1 reference